SCHEMBL7033271

SCHEMBL7033271

CCCCCOc1cc(CN2CCN(c3ccc(NC(=N)c4ccc[nH]4)cc3)CC2)cc(OCCCCC)c1O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.40
TSHR P16473 4/20 0.40
MAPK1 P28482 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
GFER P55789 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
USP2 O75604 1/20 0.36
PLA2G2A P14555 1/20 0.36
HPGD P15428 2/20 0.36
TAAR1 Q96RJ0 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6022703 0.97 MAPT (0.43) MAPTTSHRMAPK1NPC1RAB9A
SCHEMBL6022555 0.83 MAPT (0.42) MAPTTSHRMAPK1NPC1RAB9A
SCHEMBL7033277 0.82 MAPT (0.37) MAPTTSHRNPC1RAB9AMEN1
SCHEMBL6023977 0.82 MEN1 (0.49) MAPTTSHRNPC1RAB9AGFER
SCHEMBL6022692 0.81 MEN1 (0.51) MAPTTSHRNPC1RAB9AGFER
SCHEMBL6023674 0.81 MEN1 (0.51) MAPTTSHRNPC1RAB9AGFER
SCHEMBL6023689 0.81 MEN1 (0.51) MAPTTSHRNPC1RAB9AGFER
SCHEMBL6022701 0.81 MEN1 (0.51) MAPTTSHRNPC1RAB9AGFER
SCHEMBL6023941 0.81 ALDH1A1 (0.47) MAPTTSHRNPC1RAB9AGFER
SCHEMBL6023360 0.80 MAPT (0.43) MAPTTSHRMAPK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2003-08-28 US claimed
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162789-A1 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them HTT, PARK7, NQO1 MAPT 69/4885TSHR 4871/4885MAPK1 2652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.